Stay updated on Trametinib and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Trametinib and Pembrolizumab in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.5.2 replaces the previous v3.5.0.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check37 days agoChange DetectedThe page header now shows Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check66 days agoChange DetectedThis update shows a minor revision label change from v3.4.1 to v3.4.2. No substantive changes to the study details or eligibility criteria appear to have occurred.SummaryDifference0.1%

- Check73 days agoChange DetectedRevision: v3.4.1 is now displayed, replacing the previous Revision: v3.4.0.SummaryDifference0.1%

- Check80 days agoChange DetectedUI updates include adding a 'Show glossary' option and modifying metadata labels such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and updating the revision to v3.4.0 (previously v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Trametinib and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.